MDxHealth S.A. (MDXH) is a publicly traded company in the Healthcare — Medical - Diagnostics & Research industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
MDxHealth SA is a commercial-stage precision diagnostics firm delivering specialized urologic solutions across the globe. Its international footprint includes the United States, various European nations such as the Netherlands, Belgium, Spain, Poland, Italy, and the wider European Union. The company's innovative genomic testing portfolio for prostate cancer comprises SelectMDx, a non-invasive urine test, and ConfirmMDx, an epigenetic diagnostic tool.
Analysis Summary
MDxHealth S.A. reported revenue of $107.9M in the most recent fiscal year, growing at a 5-year CAGR of 42.3%.
Trailing-twelve-month margins: gross margin 57.7%, operating margin -16.6%, net margin -32.2%.
At the current price of $0.68, MDXH has negative trailing earnings (P/E not meaningful) and an ROE of 402.97%. Market capitalisation stands at $35M.
Balance sheet quality for MDXH: current ratio of 1.1, net debt of $66.1M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $0.68 |
| Market Cap | $35M |
| Exchange | NASDAQ |
| Country | BE |
Valuation Ratios
| Price / Book | -2.92 |
| EV / EBITDA | -17.51 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 402.97% |
| Return on Invested Capital | -12.74% |
| Return on Assets | -17.67% |
| Gross Margin | 57.68% |
| Operating Margin | -16.59% |
| Net Margin | -32.17% |
Financial Health
| Debt / Equity | -7.86 |
| Current Ratio | 1.08 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -2.73 |
What to look at in Healthcare / Pharma
The R&D pipeline is the invisible asset. Patents expiring = revenues evaporating. Look at innovation and cash flow.
- R&D / Revenue — Shows investment in future pipeline. Serious pharma reinvests 15-20%
- 5y EPS growth — After patent expirations, are they still growing?
- Gross margin — Branded pharma >70%. Generics much lower — defines the business type
- FCF / Net Income — Earnings quality — big pharma should convert >90%
- ROIC — Capital reinvested efficiently — key in pharma due to long R&D cycles
- Net debt / EBITDA — Pharma acquisitions pile up debt — watch the post-M&A picture
- P/E vs own 10y history — The best comparison is with its own history, not with peers
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| MDXH | MDxHealth S.A. | $35M | 403.0% | ||
| TMO | Thermo Fisher Scientific Inc. | $241.0B | 36.16 | 4.74 | 13.4% |
| 0R0H.L | Thermo Fisher Scientific Inc. | $225.7B | 32.73 | 4.11 | 12.6% |
| 0R2B.L | Danaher Corporation | $142.2B | |||
| DHR | Danaher Corporation | $140.6B | 37.04 | 2.81 | 7.7% |
| 0HAV.L | Agilent Technologies, Inc. | $49.3B | 30.43 | 5.93 | 20.5% |
| NTRA | Natera, Inc. | $46.7B | 27.16 | -12.2% | |
| IQV | IQVIA Holdings Inc. | $44.2B | 34.40 | 7.58 | 20.9% |
Price Performance
| 1 month | -9.38% |
| 3 months | +25.36% |
| Year-to-date | -80.93% |
| 1 year | -81.50% |
| 3 years | -75.95% |
52-Week Range
| 52-week High | $5.33 |
| 52-week Low | $0.40 |
| Avg Volume (90d) | 4.5M |
Related companies: ACRS · ASMB · IMRX · NEO · QTRX · SI · SNWV
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of MDXH: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks